A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)

Kamata Takeo0 个研究点目标入组 84 人开始时间: 2021年6月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•1 Diagnosis of PNH
•2 Clinically Evident Extravascular hemolysis defined by:
•Anemia, Hgb is 9.5 g per dL or less than 9.5, with absolute reticulocyte count 120000 per microL or more.
•At least 1 packed RBC or whole blood transfusion within 6 months prior to the start of the study
•3 Receiving a C5 inhibitor for at least 6 months prior to Day 1 in this study at an approved dose or higher and with no change in dose or interval for at least 24 weeks preceding Day 1. For those patients who recently switched from eculizumab to ravulizumab, they must have received at least the loading dose and 3 maintenance doses of ravulizumab preceding Day 1.
•4 Platelet count 30,000 per microL or more than 30,000 per microL without the need for platelet transfusions
•5 Absolute neutrophil counts 750 per microL or more
•6 Documentation of vaccination for Neisseria meningitidis: All patients must be vaccinated against meningococcal infections within 3 years prior to, or at the time of initiating study
•Age 18 years or older.

•1 History of a major organ transplant or hematopoietic stem cell transplantation
•2 Known aplastic anemia or other bone marrow failure that requires HSCT or other therapies including anti-thymocyte globulin and or immunosuppressants
•4 Known or suspected complement deficiency
•8 Laboratory abnormalities at screening, including:
•Alanine aminotransferase more than 2 x ULN
•Direct bilirubin more than 2 x ULN
•11 Current evidence of biliary cholestasis
•13 Estimated glomerular filtration rate less than 30 mL per min per 1.73 m2 and or are on dialysis.

发起方

Kamata Takeo